Physician profile
Emily Perdoncin
NPI 1740574557
$20,921.64
in general payments reported to CMS, 2019-2025
28 companies · $4,583 in 2025
The $4,583 reported for 2025 was more than what 82% of Interventional Cardiology providers received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,427 · 2020: $11K · 2021: $244 · 2022: $642 · 2023: $3,138 · 2024: $129 · 2025: $4,583.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,742 · Food and Beverage: $3,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,741.68 |
| Food and Beverage | $3,108.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $10,500.00 | 2020 | |
| Abbott Laboratories | $4,851.95 | 2021-2025 | Mitraclip, Navitor, Triclip |
| Edwards Lifesciences Corporation | $2,188.27 | 2022-2025 | Evoque, Pascal |
| Medtronic, INC. | $1,303.46 | 2021-2024 | Corevalve Evolut R, Symplicity G3 |
| Abiomed | $288.72 | 2019 | |
| Corindus INC. | $242.26 | 2019 | |
| Boston Scientific Corporation | $173.61 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $159.17 | 2019-2020 | |
| Cardiovascular Systems INC. | $156.31 | 2019 | |
| Amgen INC. | $134.72 | 2019-2020 | |
| Biotronik INC. | $121.92 | 2019 | |
| Novartis Pharmaceuticals Corporation | $117.53 | 2019-2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $114.80 | 2019-2022 | |
| W. L. Gore & Associates, INC. | $73.08 | 2021 | |
| Chiesi USA, INC. | $57.14 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $47.67 | 2019 | |
| Amarin Pharma, INC. | $47.24 | 2020 | |
| Sanofi-Aventis U.S. LLC | $46.04 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $39.63 | 2019-2020 | |
| Portola Pharmaceuticals, LLC | $38.52 | 2019 | |
| Philips North America LLC | $36.24 | 2020-2023 | |
| Irhythm Technologies, INC. | $31.75 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $30.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.52 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $25.77 | 2019 | |
| Actelion Pharmaceuticals US, INC. | $24.56 | 2019 | |
| Cardiva Medical, INC. | $24.15 | 2025 | Cardiva Vascade 6/7f Vcs |
| Terumo Medical Corporation | $17.69 | 2025 | Tr Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Perdoncin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.